Good day everyone, and welcome to today's ANI Pharmaceuticals First Quarter 2021 Earnings Release Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. Please note, today's call is being recorded. It is now my pleasure to turn the conference over to Lisa Wilson. Please go ahead.

Thank you, operator. Welcome to ANI Pharmaceuticals' Q1 2021 earnings results call. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer of ANI. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the Company's future performance may be considered forward-looking statements, as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to ANI Pharmaceuticals' management as of today and involve risks and uncertainties, including those noted in our press release issued this morning and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. ANI specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. The archived webcast will be available for 30 days on our website, anipharmaceuticals.com. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on May 7, 2021. Since then, ANI may have made announcements related to topics discussed, so please reference the Company's most recent press releases and SEC filings. And with that, I'll turn the call over to Nikhil Lalwani.

Thank you, Lisa. Good morning everyone, and thank you for joining our call. The first quarter of 2021 was an important period for us, as we made significant progress towards our goal of building a sustainable biopharmaceutical company to serve patients in need. We defined four pillars of our strategy and achieved important milestones, including substantial work on finalizing the Cortrophin sNDA refiling and commercial team build-out, signing a definitive agreement for the acquisition of Novitium to enhance generics R&D, and acquiring the NDAs from Sandoz to expand our branded products portfolio. This morning I will speak to these growth drivers and outline our plans to achieve our goals. Before I get into that, I hope that you and your families are safe and well, and our thoughts are with those around the world facing the crisis caused by this destructive virus. Next, let me share a couple of thoughts about the general operating environment. The biopharmaceutical industry has simultaneously been at the center of efforts to treat and prevent COVID-19 and has also been vulnerable to its overall impact. Through the first quarter of 2021, there was a continued decline in prescriptions across branded and generic segments. According to IQVIA, the generic segment declined 15% year-over-year when adjusted for a 90-day supply. This dynamic, combined with seasonal factors, has contributed to the softness in prescription levels for ANI's branded and generics products. In the first quarter of 2021, ANI achieved net revenues of $54.5 million, compared to $49.8 million in Q1 2020, and delivered adjusted non-GAAP EBITDA of $18.9 million. I would like to thank the ANI team, our partners, suppliers, customers, and advisors for their support in ensuring our medicines reach patients in need and we make strides forward on our overall strategy. On our last quarterly call, I laid out ANI's four pillars for future growth. Now I'd like to map our recent progress to each of these foundational pieces. First, our top priority remains centered on building a successful Cortrophin Gel franchise. We see Cortrophin as a transformational opportunity for the company. Cortrophin represents a new brand product with only one competitor in the same class achieving $770 million in revenues in 2020. We are eager to bring this much-needed product to patients in need. This launch has the potential to dramatically change the size and scale of our company. We continue to make solid progress achieving the key project milestones and are on track to refile our supplemental New Drug Application or sNDA in this quarter. We have every confidence that our submission package will be robust and comprehensive. In February, we brought on Chris Mutz as our Chief Commercial Officer and Head of Rare Diseases to spearhead our launch strategy and commercial plan. He brings deep experience in the successful commercialization of rare disease therapies at Alexion and Merck. He is currently building his team and most recently brought on board Bill Mroczka as VP of Market Access and Sherry Korczynski as VP of Marketing to drive launch readiness. Our second pillar is to strengthen our generics view with enhanced development capability. Last quarter, we announced our agreement to acquire Novitium, and we are on track to close that transaction in the second half of this year. We have filed a definitive proxy for a shareholder vote on June 2nd on the financing of this transaction, i.e., issuance of greater than 20% of equity to the sellers and to Ampersand Capital. As Steve will discuss later, we are on track to secure our term loan B financing, and finally, we are in the process of gaining FTC approval. As we have outlined, there are many reasons why we believe the Novitium acquisition truly represents a pivot point for ANI. Our company moves from a heavy reliance on business development deals to a company with a robust internal R&D engine. The investment thesis of adding a best-in-class R&D engine with an attractive list of new launches is already playing out. Since our announcement, Novitium has received several product approvals including limited competition opportunities such as Famotidine solution, a generic version of Pepcid, and generic Fluphenazine. For 2021 and 2022 alone, Novitium has more than 25 anticipated product launches including some with Competitive Generic Therapy designation. Furthermore, they have more than 30 additional products under development. We are pleased that the leadership team, with its proven track record of success, will be joining the ANI family to drive growth. Moving now to our third pillar, maximizing the value of established brands through programmatic business development and innovative access and go-to-market strategies. In early April, we signed and closed an accretive deal to acquire the NDAs for OXISTAT, Veregen, and Pandel, and the ANDA for ApexiCon from Sandoz. The acquisition further leverages our innovative brand commercialization infrastructure as well as our North American manufacturing footprint. Importantly, we are ensuring that patients in need continue to have access to these products. We have already begun selling these high-quality dermatology products, which generated net revenues of $13.2 million in 2020. As part of this acquisition, we also entered into a multi-year manufacturing and supply agreement for OXISTAT, Pandel, and ApexiCon. We plan to transfer the manufacturing and packaging of these products to our own manufacturing sites in the future. One note on our manufacturing facilities and capabilities. As the pandemic continues here in the U.S. and rages in other parts of the world, our North American manufacturing footprint remains increasingly relevant as supply chains become more localized. We are very pleased with our progress to date as we execute on these critical strategic initiatives. With that, I'll turn the call over to Steve to discuss our Q1 2021 financials as well as provide guidance for the year.

Thank you, Nikhil, and good morning to everyone on the line. Net revenues for the first quarter of 2021 were $54.5 million, up $4.7 million or 9.5% as compared to the $49.8 million posted in the first quarter of 2020. Sales of our generic products were $33 million during the first quarter of 2021, a decrease of 12% compared to the $37.5 million for the same period in 2020. As Nikhil mentioned in his remarks, there was softness in the pharmaceutical industry during the first quarter of this year, principally due to the COVID-19 pandemic and further compounded by seasonal factors. In response, our wholesale and retail customers continue to adjust their inventory levels to match the realities of the depressed prescription volume. These dynamics negatively impacted the market for many of our branded and generic products. In addition, the decrease reflects lower average selling prices among our generic products over the comparable period and a shift in mix towards generic products with lower average selling prices. From a product perspective, the net decrease was driven by declines in sales of Ezetimibe Simvastatin, Methazolamide, Miglustat, and Diphenoxylate, tempered somewhat by increased revenues from the sales of Paliperidone ER and E.E.S. Net revenues for our branded products were $7.5 million during the first quarter of 2021, a decrease of 17.9% compared to $9.2 million for the same period in 2020. The decrease primarily reflects lower unit sales of Inderal XL and InnoPran XL, tempered by increased sales Casodex and Inderal LA. Royalty and other revenues were $11.4 million during the first quarter of 2021, an increase of $10.3 million from $1.1 million in the same period in 2020. This increase is due to the recognition of ANI's contractual share of royalties due for patent rights related to Kite Pharma's oncology product YESCARTA. The revenue recorded in the period is the direct result of the recent resolution of certain litigation between Kite and the third-party entity with which ANI has its direct contractual royalty relationship. We will receive $12.3 million of cash related to this transaction in May and as such this amount is in accounts receivable as of the balance sheet date. Our cost of sales excluding depreciation and amortization decreased by $1.8 million or 8.3% to $20 million in the first quarter of 2021 from $21.8 million for the same period in 2020. The decrease primarily reflects the non-recurrence of $2.7 million in cost of sales representing the excess of fair value over cost for inventory acquired in the Amerigen acquisition and recognized in the first quarter of 2020. The decrease was tempered by a $500,000 increase in royalty expense due to an increase in sales of products subject to profit-sharing arrangements. Excluding the impact of the prior year step-up of the Amerigen inventory, cost of sales as a percentage of net revenues decreased to 36.7% during the first quarter of 2021 from 38.4% during the same period in 2020, primarily as a result of royalty revenue of $11.2 million with no associated cost of sales during the three months ended March 31, 2021. Research and development expense decreased in the first quarter of 2021 to $3 million, compared with $6.3 million in the first quarter of 2020, primarily due to the non-recurrence of the $3.8 million in-process research and development charge recorded as a component of day-one accounting for the Amerigen acquisition during the first quarter of 2020. Selling, general and administrative expenses increased from $13.7 million to $17.6 million, an increase of $3.9 million or 28.5%, primarily due to $2.9 million of transaction expenses related to the pending Novitium acquisition incurred in the three months ended March 31, 2021. Expenditures on the Cortrophin pre-launch inventory were minimal in the current quarter as compared to $4.6 million in the prior year, due to the timing of activities with our supply chain partners. Adjusted non-GAAP EBITDA was $18.9 million in the first quarter, up $1.3 million or 7.6% from the comparable period in 2020. As detailed on Table 4 of this morning's press release, our adjusted non-GAAP diluted earnings per share is $1.04 for the quarter flat with the prior year period. We generated $20.7 million of cash flow from operations in the current year period, and as of March 31, 2021, we had $21.5 million of unrestricted cash and cash equivalents. Total net debt as of March 31, 2021 decreased to $159.5 million as compared to $179.1 million as of December 31, 2020. This figure represents 2.3 times net leverage on a trailing 12-month basis. I'm also pleased to mention that in April, we received inaugural ratings from the two major rating agencies Moody's and S&P. Moody's assigned a B2 rating with a stable outlook, and S&P Global Ratings assigned a B+ rating with a positive outlook. Establishing the Company with Moody's and S&P represents another milestone in the maturation of the company and forms the foundation for the syndication of our $300 million term loan B and $40 million credit facility with Truist in support of the Novitium acquisition. Finally, when we last met with you on our March 9th conference call, we re-instituted annual guidance. At that time, we indicated the following full year 2021 figures for ANI standalone prior to giving effect to the Novitium transaction: net revenues of $207 million to $218 million, adjusted non-GAAP EBITDA of $60 million to $65 million, and adjusted non-GAAP diluted earnings per share of between $3.30 and $3.59 per diluted share. It was highlighted at that time that these guidance figures assume the total U.S. pharmaceutical prescription activity rebounds to pre-COVID-19 levels. The first-quarter actual results just discussed are a clear indicator that volume levels in the U.S. generic market continue to be impacted. With that said, we remain cautiously optimistic that we can achieve our originally stated financial goals and therefore reiterate our full year guidance, albeit with a current orientation towards the low end of the range. As was before, any sustained COVID-19 suppression of script activity will adversely impact our ability to reach these goals. I'll now open up the call for questions. Operator, please go ahead with the instructions.

We take today's first question from Elliot Wilbur with Raymond James. Please proceed.

Thank you, good morning. Busy morning juggling some different calls here. I apologize Steve if I missed this in your prepared commentary, but just some color on the swing in YESCARTA royalties and why the large impact this quarter and that's just a one-time item and things revert to normal after that? And then I also want to ask a question on operating cash flow. I think it was just over $20 million in the quarter which is a pretty strong first quarter for the company at least by historical standards. So I mean that's just kind of a timing issue in terms of maybe receivables collection, but any additional color that you could provide there would be helpful? Then I've got a couple of follow-ups for Nikhil which I'll hold off until you respond.

Sure. Good morning, Elliot. Nice to speak to you. So, yeah, on the royalty revenue line item there was a settlement that occurred at the level above ANI's, so between Kite and the entity that we receive our royalties directly from. And so that revenue triggered a royalty to ANI in the quarter and was recognized as such. And so we do anticipate that this is the last royalty event related to YESCARTA for the company. And you'll find we just posted our 10-Q out on the SEC website. If you look in the revenue recognition section of the 10-Q this morning, you'll see a bit further color on that transaction. And then, yeah, we were very pleased with the cash flow in the quarter at above $20 million for the quarter. Yeah, and you're right, if you look at quarterly cash flow for the company, right, it can be a little bit lumpy as the quarters tick on. We are pleased to have a strong cash flow quarter this go around. I don't think there is anything specific to highlight about the $20 million. It was all operational and nothing specific. And to be clear, as we said in the prepared comments, the $20 million that was generated in the quarter does not include the cash that will be received for the YESCARTA royalty. So we will be receiving over $12 million here in the month of March related to that transaction and you'll see that reflected in the second quarter cash flows.

Okay. I apologize. I actually have one additional question for you. Just what's happening on the branded side of the business, just looking at the sequential decline obviously off trend is that function of just lower units, lower pricing, lower trade inventory? Is that a new run rate or is that somewhat anomalous?

Sure. In terms of the...

Hey Steve, why don't I take that?

Yeah. You want to grab that Nikhil? Sure.

Yeah, yeah. So thank you and good morning, Elliot. I think that in terms of the brand business, there are two things that clarify here. I think first is in response to your question, the drop Q-on-Q is largely related to units and we believe that there is an impact of reduced prescriptions and a COVID-related impact. We have seen a bit of an uptick in the month of April since then. So to your point on is this the expected run rate going forward. And I think the second thing is, as you know well, Elliot, part of our growth for our brand business has been doing deals almost every year and we just signed and closed the PharmaDerm deal which will be the driver of growth through the rest of the year. And so I just wanted to add that.

Yeah. Thanks. And I just had two quick follow-ups for you. Could you just talk a little bit more about the PharmaDerm deal, interesting basket of assets, you guys haven't had any presence in the topical space historically just sort of curious as to what motivated that, was it just purely opportunistic or is that more of a calculated strategic move to enter a dosage form category where frankly a lot of the bigger important players have pulled back fairly substantially? And then just my last question is on Novitium, they've been on a bit of a win streak in terms of recent approvals Famotidine, obviously very interesting just given the size of that market and kind of, what's happening there. I'm assuming these are sort of consistent with what you had anticipated when you were doing your diligence, but just sort of curious I guess specifically on Famotidine looks like it could be a fairly important opportunity just kind of given the overall market and limited competition there. Just sort of wondering maybe how that transpired versus the expectations that were established during your diligence? Thanks.

Yes. Thank you again, Elliot. So, I'll take your second question first which is on Novitium. Yes, they — absolutely, the investment thesis is playing out as we had planned with the world-class R&D engine headed by Samy delivering multiple new launches: Fluphenazine, Famotidine, Meloxicam, and Dicyclomine. I think these are all limited competition. Famotidine obviously stands out. And then in terms of how this compares with our diligence or plan, I think it's probably on the positive side. This is a good run. When you look at these portfolios in aggregate, there are puts and takes and they're right now just on a streak of wins. And I think that that is again a testament to the thesis that this is a world-class R&D engine and team and they are delivering and this is just a continuation of a strong track record that they have built over the years. We look forward to welcoming the entire Novitium team to the ANI family and to moving forward and driving growth together. So that's on the Novitium acquisition and their launches. And then on PharmaDerm, look, I think it's a combination of two things. I think one is as you know, over the years ANI has built a strong muscle in programmatic business development and continuously scanning the market to see what interesting opportunities are out there. This was an interesting opportunity that came up with Sandoz making a strategic decision to go in a different direction with their derm business. The advantage it has is it has the ability to leverage our commercialization infrastructure. It has the ability for us to leverage our manufacturing infrastructure, so we have a three-year supply agreement with Sandoz, but going forward we can transfer it to our own manufacturing. So, strategically, it aligns with how we think about these opportunities. And then that's why we did the PharmaDerm deal.

Thank you. We'll take our next question from Dana Flanders with Guggenheim Partners. Please go ahead.

Hi, this is Devin on behalf of Dana. Thanks for the questions. Just a couple for me. First, I know some peers have referenced generic price erosion; I think you alluded to that in your comments. Just trying to get a sense of what generic pricing trends you're seeing and typically able to quantify the impact on generic growth for the quarter driven by volume declines versus price erosion?

I can take that one, Nikhil. On a year-over-year basis, we saw about 6% price erosion in our overall generic franchise for the year-over-year period.

Thank you. Regarding gross margins, it appears that they were higher on both a year-over-year and sequential basis, primarily due to the one-time royalty for YESCARTA. Can you provide some insights on how you expect margins to compare for the year in relation to Q1 levels?

Yes sure. So, yes, the first-quarter margin profile did benefit from the royalty item. In terms of our full year margins, we would continue to see kind of mid to high 50% range for the remainder of the year.

Okay. And then the last one for me. Just on Cortrophin, can you talk a little bit more about your preparations and commercial readiness ahead of potential launch? I know you started manufacturing earlier this year. Do you anticipate that you will be able to immediately launch following approval in the second half, or are there any other gating factors that may push the launch into 2022?

Yes, Nikhil?

Yes. So, let me take that, Steve. Thank you for your questions. Nice to meet you. I think that on Cortrophin in the refiling we are in the sort of final phases of putting our refiling sNDA together and are on track. We're compiling the information, we're reviewing the information, we've obviously got a dedicated team and external consultants that are helping us put the package together. We remain in continued touch and engagement with the FDA to get any clarifications to ensure that our package is as robust and comprehensive as possible. We remain confident of being able to refile in this quarter. With regards to launch timing, I think we've not given guidance on that. The regulatory pathway will follow – will file in this quarter. But as in terms of being able to launch once we get approval, that is absolutely the plan. We have the manufacturing that is being done in preparation for that, and also we're ramping up our commercial team as we – as I spoke about in my prepared remarks. We have Chris Mutz as Head of Rare Disease and he is building out his team for market access, marketing and sales, and we are absolutely preparing to launch as soon as we get approval.

Okay. Thank you very much.

We'll go next to Brandon Folkes with Cantor Fitzgerald. Please go ahead.

Hi. Thanks for taking my questions. So maybe just firstly, post the close of the Novitium acquisition, how do you think about capital allocation priorities post that close? Is business development still going to be as key, or do you think it could take a bit of a back seat to investing in R&D behind Novitium? Just any color there would be great. Maybe just one clarifying question here, so on this YESCARTA revenue payment, is this something that was contemplated in the initial guidance range? Just any color there.

Yes. So Steve, why don't I take the first one, and you can take the second?

Perfect.

Yes. So on capital allocation going forward, the idea behind the Novitium acquisition is very much to reduce the reliance on business development entirely and to have a growth engine that is internal to the company that is in our full control and that is the intent. Having said that, we will allocate an appropriate amount of capital for the Novitium R&D engine and for the overall ANI R&D engine. And as far as business development, look, this is a core strength and capability of the company, being able to source, diligence, get the deal done, and then integrate and deliver. That is a strength that I would love to retain, and we'll continue to do that. Again, we will continue to scan the market and be open for deals. I think to reiterate something that we've said all along, this is about as rich an environment from a targets and assets perspective as we have ever seen, so we'll continue to look at that. However, from a capital allocation perspective, absolutely, we will back the R&D engine all the way behind the acquisition. Steve?

Yes. And on the YESCARTA royalty, Brandon, and good morning. That item was not fully contemplated in our original guidance range that we gave at the last call.

Thank you very much to both of you. Maybe one more follow-up if I can just be tackling one of the earlier questions from a bit of a different angle. Your interactions or sort of the environment you're seeing anything that would lead you to think that the review for Cortrophin may not be a six-month review? And then secondly, any color on the shelf life of your Cortrophin? Thank you.

Yes, let me take that. And thank you again, Brandon, and good morning. Look, shelf life is something that we will not comment on. We understand that our competitors may listen in on this stuff, so I think we'll try to steer clear of that. And in terms of the review period with the FDA, look, we're putting together as comprehensive a package and as robust a package as we can think of. We are making sure that it's the best thinking of our team and best thinking of the world-class consultants that are advising us on our refiling and couple that with active engagement with the FDA. I think we feel therefore very confident that we're putting forth a very comprehensive and robust package. I'll remind you that as we were doing the Novitium transaction, the sellers, as well as the private equity firm that did the PIPE, Ampersand, both had – as part of diligence, saw everything, and they had external experts look at our files and our plans. The recommendation to their clients, i.e., the sellers of Novitium, as well as Ampersand, was to go ahead and invest in the equity of ANI. So that should give you light that there are many sets of eyes and experts looking at this. We're actively engaged with the FDA, and we're taking the time to put the best package forward.

Great. Thank you very much to both of you and congrats on the progress taking over.

Thank you, Brandon.

It appears we have no further questions. I will return the floor to Nikhil Lalwani for closing remarks.

Thank you, Keith. I'm pleased with the progress we've made in a short time and under challenging industry conditions. We look forward to updating you, as we advance Cortrophin. We are thrilled about the prospects of ramping our internal research and development capabilities for the Novitium acquisition. As a company, we will continue to seek out opportunities for growth along the four defined pillars of our strategy. We appreciate very much your ongoing support as we work to deliver value to shareholders and bring important therapeutics to patients in need. Thank you all for your time today and stay safe. Thank you.

Thank you.

This does conclude today's program. Thanks for your participation. You may now disconnect.